BRPI0515518A - análogos de loxapina e métodos de usos dos mesmos - Google Patents

análogos de loxapina e métodos de usos dos mesmos

Info

Publication number
BRPI0515518A
BRPI0515518A BRPI0515518-5A BRPI0515518A BRPI0515518A BR PI0515518 A BRPI0515518 A BR PI0515518A BR PI0515518 A BRPI0515518 A BR PI0515518A BR PI0515518 A BRPI0515518 A BR PI0515518A
Authority
BR
Brazil
Prior art keywords
methods
loxapine
analogues
relates
novel compounds
Prior art date
Application number
BRPI0515518-5A
Other languages
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of BRPI0515518A publication Critical patent/BRPI0515518A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

"ANáLOGOS DE LOXAPINA E MéTODOS DE USO DOS MESMOS". A invenção relaciona-se aos novos compostos e métodos de utilizá-los para modular o sono.
BRPI0515518-5A 2004-09-21 2005-09-21 análogos de loxapina e métodos de usos dos mesmos BRPI0515518A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
PCT/US2005/034015 WO2006034414A2 (en) 2004-09-21 2005-09-21 Loxapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0515518A true BRPI0515518A (pt) 2008-07-29

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515518-5A BRPI0515518A (pt) 2004-09-21 2005-09-21 análogos de loxapina e métodos de usos dos mesmos

Country Status (19)

Country Link
US (3) US20060063755A1 (pt)
EP (1) EP1804804B1 (pt)
JP (1) JP5049129B2 (pt)
KR (1) KR101264444B1 (pt)
AT (1) ATE542536T1 (pt)
AU (1) AU2005286713B2 (pt)
BR (1) BRPI0515518A (pt)
CA (1) CA2580250C (pt)
CY (1) CY1112590T1 (pt)
DK (1) DK1804804T3 (pt)
EA (1) EA012610B1 (pt)
ES (1) ES2378452T3 (pt)
MA (1) MA28985B1 (pt)
MX (1) MX2007003032A (pt)
NO (1) NO20071604L (pt)
NZ (1) NZ553900A (pt)
PL (1) PL1804804T3 (pt)
PT (1) PT1804804E (pt)
WO (1) WO2006034414A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
SG159390A1 (en) * 2003-01-23 2010-03-30 Acadia Pharm Inc Use of n-desmethyclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2005063254A2 (en) 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
WO2006049734A2 (en) * 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
DK2343286T3 (en) * 2006-10-28 2015-04-13 Methylgene Inc Dibenzo [b, f] [1,4] oxazepine derivatives as inhibitors of histone deacetylase
CN101641350B (zh) * 2007-03-15 2012-11-28 ARYx医疗有限公司 二苯并[b,f][1,4]氧杂氮杂*化合物
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
KR20110086132A (ko) 2008-11-07 2011-07-27 인슐린 메디컬 엘티디 약물 전달 장치 및 방법
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
NZ735777A (en) 2015-03-26 2023-03-31 Jacqueline M Iversen Methods and compositions to inhibit symptoms associated with veisalgia
BR112022007503A2 (pt) * 2019-10-21 2022-07-12 Alairion Inc Derivados de ácido 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-il)piperazin-1-il)- e 3-(4-(11h-dibenzo[b,f][1,4]oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)-propanoico como moduladores de receptor de h1 e 5-ht2a para o tratamento de distúrbios do sono
WO2025076527A1 (en) * 2023-10-07 2025-04-10 Inspire Medical Systems, Inc. Pulmonary therapy for sleep disordered breathing care

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (pt) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
WO2003039255A1 (en) 2001-11-05 2003-05-15 Basf Aktiengesellschaft Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
JP2006510697A (ja) * 2002-12-20 2006-03-30 ビーエーエスエフ　アクチェンゲゼルシャフト 殺虫性ジベンゾ（ヘテロ）アゼピン誘導体
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
NZ553900A (en) 2010-10-29
AU2005286713B2 (en) 2010-10-28
JP2008513510A (ja) 2008-05-01
EP1804804A4 (en) 2010-11-24
DK1804804T3 (da) 2012-02-20
ATE542536T1 (de) 2012-02-15
CY1112590T1 (el) 2016-02-10
JP5049129B2 (ja) 2012-10-17
EA012610B1 (ru) 2009-10-30
NO20071604L (no) 2007-06-20
EA200700702A1 (ru) 2007-10-26
EP1804804A2 (en) 2007-07-11
US20060063928A1 (en) 2006-03-23
MA28985B1 (fr) 2007-11-01
WO2006034414A3 (en) 2006-09-08
PT1804804E (pt) 2012-03-30
KR101264444B1 (ko) 2013-05-20
CA2580250C (en) 2013-05-14
US7592333B2 (en) 2009-09-22
WO2006034414A2 (en) 2006-03-30
EP1804804B1 (en) 2012-01-25
AU2005286713A1 (en) 2006-03-30
US20090186872A1 (en) 2009-07-23
PL1804804T3 (pl) 2012-08-31
US8101596B2 (en) 2012-01-24
KR20070060126A (ko) 2007-06-12
ES2378452T3 (es) 2012-04-12
MX2007003032A (es) 2007-05-21
US20060063755A1 (en) 2006-03-23
CA2580250A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
BRPI0513916A (pt) moduladores de pirrol-piridina cinase
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE502005010152D1 (de) Stabilisierungseinrichtung zur dynamischen Stabilisierung von Wirbeln
DK1565136T3 (da) Sammensætninger for transdermal oxybutynin-terapi
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE60327306D1 (de) Modifizierter russ
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE388635T1 (de) Verwendung von menadione zur verstärkung der wirksamkeit von agrochemikalien
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: HYPNION, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090112759/RJ DE 02/12/2009.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]